Study Details
Design, interventions, and primary outcomes
About This Study
This is a prospective observational cohort study conducted at Fundación CTIC in Bogotá, Colombia. It characterizes the oral, fecal and intratumoral microbiome of Colombian adults with advanced solid tumors (gastric, colorectal, breast, cervical and head-and-neck cancer) who receive first-line immunotherapy as standard of care, and compares them with healthy volunteers. Using multi-omics (HiFi metagenomics, 16S, tumor RNA-Seq and untargeted metabolomics), the study aims to identify microbial signatures associated with treatment response and survival, building the initial Colombian cohort of a Cancer Microbiome Atlas with Latin American projection.
Design
Interventions / Regimen
- Drug: First-line immunotherapy (immune checkpoint inhibitors), INVIMA-approved, standard of care — Exposure observed: first-line immunotherapy with immune checkpoint inhibitors administered as standard of care (INVIMA-approved); no experimental intervention is assigned by the study. Healthy controls receive no immunotherapy.
Primary Outcomes
- Oral, fecal and intratumoral microbiome signatures associated with objective tumor response (RECIST 1.1) to first-line immunotherapy (Baseline (V0) and through 12 months)
- Differences in microbiome composition and diversity between cancer patients and healthy controls (Baseline (V0))
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-06-11
Completion: 2029-08-30
Sex: ALL
Volunteers: true
Enrollment: 150 (ESTIMATED)
Collaborators: American Society of Clinical Oncology
- Andrés F Cardona, MD, MSc, PhD, MBA (PRINCIPAL_INVESTIGATOR) - Fundación CTIC - Centro de Tratamiento e Investigación sobre Cáncer Luis Carlos Sarmiento Angulo
- Drug: First-line immunotherapy (immune checkpoint inhibitors), INVIMA-approved, standard of care — Exposure observed: first-line immunotherapy with immune checkpoint inhibitors administered as standard of care (INVIMA-approved); no experimental intervention is assigned by the study. Healthy controls receive no immunotherapy.